Clinical Trial Update: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing dalpicilib plus cetuximab versus cetuximab alone in HPV-negative, anti-PD-1-resistant recurrent/metastatic head and neck squam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Dalpicilib

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING